Oncotelic Therapeutics, Inc.

AGOURA HILLS, CA · Biotech · Public

Immunotherapy drug candidates and molecular nanomedicine platform using AI-guided drug development

Claim this profile

Follows are private to you and power your alerts

Updated · oncotelic.com

Sector
Biotech
Headquarters
AGOURA HILLS, CA
Latest Form D
$275K, Dec 2025
Total capital
$40.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$40.3M
7 Form D · last Dec 2025
10 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
1 pending · first 2022
Rank in peer group#481 of 1462

Capital timeline

20102012201420162018202020222024FEDERAL ↑EQUITY ↓Cumulative $45.3M1st Form D$7.5M2nd Form D$2.9M3rd Form D$600K4th Form D$27M5th Form D$2M6th Form D$5M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$275K
  • Offering registeredForm D · SEC · 6th filing$5M
  • Private capital raisedForm D · SEC · 5th filing$2M
  • Private capital raisedForm D · SEC · 4th filing$27M
  • Private capital raisedForm D · SEC · 3rd filing$600K
  • Private capital raisedForm D · SEC · 2nd filing$2.9M
  • Private capital raisedForm D · SEC · 1st filing$7.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3390OPUS GENETICS INC.—$46.9M
3391CERo Therapeutics, Inc.—$44.6M
3392Forte Biosciences—$44.1M
3393Oncotelic Therapeutics, Inc.—$40.3M
3394ADVANTAGENE, INC—$35.9M
3395Allarity Therapeutics, Inc.—$26.9M
3396OTHRAM, INC.—$31.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 21 related persons
  • David ChaplinDirector · Executive Officer
  • Seymour FeinExecutive Officer
  • Roy FicklingDirector
  • Mark KesselDirector
  • Peter LangeckerExecutive Officer
  • Matthew LoarExecutive Officer
  • Anthony MaidaExecutive Officer
  • James MurphyExecutive Officer
Show all 21 people
  • Chuho ParkExecutive Officer
  • Chulho ParkExecutive Officer
  • Simon PedderDirector
  • Donald ReynoldsDirector
  • Bobby Sandage, Jr.Director
  • Saran SaundExecutive Officer
  • William SchwietermanDirector · Executive Officer
  • Amit ShahExecutive Officer
  • William ShieblerDirector
  • Vuong TrieuDirector · Executive Officer
  • VUONG TRIEUDirector · Executive Officer
  • Fatih UckunExecutive Officer
  • Alastair WoodDirector

Patents

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.